Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is associated with particularly poor outcomes in the elderly population, in whom the disease is most prevalent. BCL-2 has been identified as an antiapoptotic protein and promotes survival of leukemia stem cells. Recently, the United States FDA has approved venetoclax, a...

Full description

Bibliographic Details
Published in:	Case Reports in Hematology
Main Authors:	Aaron M. Lee, Aaron M. Goodman, James K. Mangan
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Online Access:	http://dx.doi.org/10.1155/2022/2802680

Similar Items

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
by: Ibrahim Aldoss, et al.
Published: (2019-12-01)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024-07-01)

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2018-09-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
by: Nickolas Steinauer, et al.
Published: (2024-03-01)

P090 | ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS: A RETROSPECTIVE, MONOCENTRIC STUDY.
by: A. Bruzzese, et al.
Published: (2025-09-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
by: Abhishek Maiti, et al.
Published: (2020-06-01)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
by: Di Wu, et al.
Published: (2021-01-01)

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
by: Wenxiu Shu, et al.
Published: (2025-05-01)

Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents
by: Sabine Kayser, et al.
Published: (2024-10-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-06-01)

P067 | CARDIAC EVENTS IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT: A MONOCENTRIC EXPERIENCE
by: L. Esposito, et al.
Published: (2025-09-01)

Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis
by: Yi Chen, et al.
Published: (2025-12-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
by: Naseema Gangat, et al.
Published: (2023-03-01)

DP093 | HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX IN VERY ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS: IS LESS BETTER THAN MORE?
by: F. Tarantini, et al.
Published: (2025-09-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
by: Talha Badar, et al.
Published: (2024-02-01)

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
by: Gianluca Martini, et al.
Published: (2023-08-01)

DP025 | INDUCTION THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: INNOVATIONS IN THE ERA OF HYPOMETHYLATING AGENTS AND VENETOCLAX COMBINATION THERAPY
by: L. Forlani, et al.
Published: (2025-09-01)

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
by: Fei Xin, et al.
Published: (2024-12-01)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
by: Minerva Montalvo Saavedra, et al.
Published: (2023-08-01)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
by: Fangli Chen, et al.
Published: (2023-08-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

P572: VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE
by: K. Sanber, et al.
Published: (2022-06-01)

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemia
by: Kathelijn Verdeyen, et al.
Published: (2025-09-01)

PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
by: Sabine Kayser, et al.
Published: (2023-08-01)

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
by: I. Johnson, et al.
Published: (2022-06-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
by: Carlos Jiménez-Vicente, et al.
Published: (2025-01-01)

Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia
by: Yi Wang, et al.
Published: (2025-04-01)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
by: Keyuan Zhang, et al.
Published: (2023-10-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

EFFICACY OF ANTIFUNGAL PROPHYLAXIS IN PREVENTING INVASIVE FUNGAL INFECTIONS IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX AND HYPOMETHYLATING AGENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: PRC Passos, et al.
Published: (2024-10-01)

P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.
by: Carlos Jimenez-Vicente, et al.
Published: (2023-08-01)

Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis
by: Yun Liu, et al.
Published: (2025-05-01)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
by: Jian Zhang, et al.
Published: (2023-08-01)

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients
by: Ludan Zhang, et al.
Published: (2024-05-01)

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
by: Nicholas J. Short, et al.
Published: (2025-10-01)